To further clarify the effect of co‐overexpression of the PGAP3 and ERBB2 in GC patients, we assigned the GC patients into four groups according to gene expression in GC tissues as follows: PGAP3‐low/ERBB2‐low, PGAP3‐low/ERBB2‐high, PGAP3‐high/ERBB2‐low and PGAP3‐high/ERBB2‐high (Figure 2E). This evidence concerns the gene PGAP3 and gastric cancer.